Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation
dc.availability.bitstream | embargoed | |
dc.check.date | 2022-09-30 | |
dc.contributor.advisor | Plant, Barry | en |
dc.contributor.advisor | Eustace, Joe | en |
dc.contributor.author | Ronan, Nicola J. | |
dc.contributor.funder | Seventh Framework Programme | en |
dc.date.accessioned | 2021-09-15T14:56:45Z | |
dc.date.available | 2021-09-15T14:56:45Z | |
dc.date.issued | 2020-09-12 | |
dc.date.submitted | 2020-09-12 | |
dc.description.abstract | CF represents one of the success stories of modern medicine with sustained incremental increases in survival from one of childhood death to one of adulthood survival. Traditionally the management of CF has focused on treating the consequences of CFTR dysfunction. The advent of ivacaftor offers the opportunity to evaluate the effect of restoration of CFTR function on CF lung disease and extrapulmonary manifestations. Global prevalence of the G551D mutation is 4%. Prevalance at Cork CF centre is 23%. Thus this work evaluates the effect of CFTR modulation on clinical parameters, Chest CT, lung microbiota, gut microbiota, gut inflammation, pancreatic function and benefit to the individual patient. | en |
dc.description.status | Not peer reviewed | en |
dc.description.version | Accepted Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | Ronan, N. J. 2020. Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation. PhD Thesis, University College Cork. | en |
dc.identifier.endpage | 265 | en |
dc.identifier.uri | https://hdl.handle.net/10468/11923 | |
dc.language.iso | en | en |
dc.publisher | University College Cork | en |
dc.relation.project | info:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/603038/EU/Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified./CFMATTERS | en |
dc.rights | © 2020, Nicola J. Ronan. | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
dc.subject | CFTR modulation | en |
dc.subject | Cystic fibrosis | en |
dc.subject | Ivacaftor | en |
dc.title | Clinical outcomes of real-world Kalydeco (ivacaftor); Cork study - understanding the implications of CFTR modulation | en |
dc.type | Doctoral thesis | en |
dc.type.qualificationlevel | Doctoral | en |
dc.type.qualificationname | PhD - Doctor of Philosophy | en |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- NR thesis.pdf
- Size:
- 5.37 MB
- Format:
- Adobe Portable Document Format
- Description:
- Full Text E-thesis
Loading...
- Name:
- 104827821 submission form - Nicola Johanna Ronan.pdf
- Size:
- 369.42 KB
- Format:
- Adobe Portable Document Format
- Description:
- Submission for Examination Form
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 5.2 KB
- Format:
- Item-specific license agreed upon to submission
- Description: